TK
Therapeutic Areas
NurExone Biologic Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ExoPTEN | Acute Spinal Cord Injury | Preclinical |
| ExoPTEN‑Glaucoma | Acute Glaucoma | Preclinical |
Leadership Team at NurExone Biologic
LS
Lior Shaltiel, PhD
Chief Executive Officer & Director
EO
Eran Ovadya, MBA
Chief Financial Officer
IS
Ina Sarel, PhD
Head of CMC, Quality and Regulation
RP
Ram Petter, PhD, MBA
Head of Operations
YD
Yoram Drucker
Co‑Founder, Chairman & VP Strategic Development
EG
Eyal Gabbai
Director